O012: Can DAV132, a medical device targeting an adsorbent to the late ileum, decrease significantly the impact of antibiotics on the fecal microbiota?

descriptionPublicationkeyboard_double_arrow_right Article , Other literature type 01 Jun 2013 English Publisher:Springer Science and Business Media LLCJournal:Antimicrobial Resistance and Infection Control, volume 2 (eissn: 2047-2994,

Copyright policy )

Authors: Grall, N; Chachaty, E; Sayah-Jeanne, S; de Gunzburg, J; Andremont, A;

doi: 10.1186/2047-2994-2-s1-o12

O012: Can DAV132, a medical device targeting an adsorbent to the late ileum, decrease significantly the impact of antibiotics on the fecal microbiota?

- Summary
- Subjects
- Related research
  (9)
- Metrics

Abstract

During antibiotic treatments a fraction of the dose impacts the intestinal microbiota, promoting spread of resistant bacteria (RB). Antibiotics can be inactivated by adsorption. DAV132 is an oral medical device to deliver an adsorbent in the late ileum. We investigated if DAV132 could reduce fecal antibiotics and RB excreted.

Related Organizations

Keywords

Oral Presentation

9 Research products, page 1 of 1

A Colon‐Targeted Adsorbent (DAV132) Does Not Affect the Pharmacokinetics of Warfarin or Clonazepam in Healthy Subjects
2021IsAmongTopNSimilarDocuments
LB-5. DAV132 Protects Intestinal Microbiota of Patients Treated with Quinolones, a European Phase II Randomized Controlled Trial (SHIELD)
2020IsAmongTopNSimilarDocuments
Faculty Opinions recommendation of Targeted adsorption of molecules in the colon with the novel adsorbent-based medicinal product, DAV132: A proof of concept study in healthy subjects.
2016IsAmongTopNSimilarDocuments
Targeted adsorption of molecules in the colon with the novel adsorbent‐based Medicinal Product, DAV132: A proof of concept study in healthy subjects
2014IsAmongTopNSimilarDocuments
DAV132, an Adsorbent-Based Product, Protects the Gut Microbiome and Prevents Clostridium difficile Infections During Moxifloxacin Treatments
2015IsAmongTopNSimilarDocuments
Protection of the human gut microbiome from antibiotics
2017IsAmongTopNSimilarDocuments
An open randomized multicentre Phase 2 trial to assess the safety of DAV132 and its efficacy to protect gut microbiota diversity in hospitalized patients treated with fluoroquinolones
2022IsAmongTopNSimilarDocuments
A Phase 3 Randomized Controlled Trial (MICROCARE) to Evaluate the Efficacy of DAV132 in Preventing Clostridioides Difficile Infection in Patients with Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome and Treated with Intensive Chemotherapy
2021IsAmongTopNSimilarDocuments
Modeling the Effect of DAV132, a Novel Colon‐Targeted Adsorbent, on Fecal Concentrations of Moxifloxacin and Gut Microbiota Diversity in Healthy Volunteers
2020IsAmongTopNSimilarDocuments

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	0
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average